News Room

FOR IMMEDIATE RELEASE

GEORGE MASON UNIVERSITY’S CAP-CLIA LABORATORY UTILIZES
AUSHON BIOSYSTEMS’ ARRAY TECHNOLOGY FOR INDIVIDUALIZED AND
TARGETED TREATMENT FOR CANCER PATIENTS

Burlington, MA, July 12, 2007 – In a cooperative effort to promote the development of personalized medicine based on reverse-phase protein array technology, Aushon BioSystems has placed a 2470 Arrayer in a CAP-CLIA laboratory established by George Mason University. Mason’s CAP-CLIA laboratory, under the direction of Profs. Lance Liotta and Emanuel Petricoin, is focused on trials of clinical cancer treatments based on an individual’s unique protein expression profile. The new 2470 Arrayer joins several other 2470s in service at Mason.

Dr. John Austin, Co-Founder and Executive Vice President, Chief Scientific Officer of Aushon BioSystems, said “We are very pleased to assist Mason with the development of this ground-breaking application of personalized medicine using protein expression.”

Dr. Lance Liotta, co-Director of Mason’s Center for Applied Proteomics and Molecular Medicine, added: “We believe that the 2470 arrayer is a superior platform that will provide the highest quality data for our translational work, and are very excited to be able to collaborate with Aushon.”

About Aushon BioSystems
Aushon BioSystems provides advanced microarray products, instruments and services for life science research, drug discovery/development and clinical diagnostics. The Company's proprietary 2470 Arrayer -- now used in leading research centers around the world -- enables researchers in the life science and pharmaceutical industries to create high quality arrays ranging from DNA to lysates. Aushon BioSystems is a privately held company based in Billerica, MA.

For more information about Aushon BioSystems, please visit the company's website at http://www.aushon.com.

About the Center for Applied Proteomics and Molecular Medicine
The Center for Applied Proteomics and Molecular Medicine at George Mason University focuses on the discovery and identification of biomarkers for early disease detection and risk assessment and the analysis of molecular pathways in diseased tissue to determine individualized and targeted treatment for patients. Results of the research will then be translated directly into patient management and care through clinical research and innovative clinical trials, with a vision toward creating a new paradigm to personalize medical treatment resulting in a positive impact on public health.